Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | ACHE | P22303 | 4/20 | 0.64 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523015 | 1.00 | MTNR1A (0.68) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3391773 | 0.96 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3395108 | 0.95 | CA1 (0.64) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL2079654 | 0.90 | KMT2A (0.56) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL10253556 | 0.84 | MTNR1A (0.61) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3854031 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL545630 | 0.80 | BRAF (0.53) | MTNR1AMTNR1BHDAC8 | |
| SCHEMBL5522805 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BKMT2AMEN1HDAC8 | |
| SCHEMBL3392060 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BKMT2AMEN1HDAC8 | |
| SCHEMBL3390898 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BKMT2AMEN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241811-B2 | E.g., 1-(pyridin-4-ylcarbamoyl)-1,2,3,6- tetrahydropyridine hydrochloride; therapy and prophylaxis of amnesia or dementia | ASTELLAS PHARMA INC. (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7037942-B2 | Amide compounds for the potentiation of cholinergic activity | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060058396-A1 | Amide compounds for the potentiation of cholinergic activity | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | US | disclosed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1159258-B1 | AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040048904-A1 | Amide compounds for the potentiation of cholinergic activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-6664293-B2 | For treatment and/or prevention of disorders in the central nervous system, particularly amnesia, dementia, Alzheimer's dementia | FUJIWAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030096847-A1 | Amide compounds for the potentiation of cholinergic activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048904-A1 | Amide compounds for the potentiation of cholinergic activity | CHAT, CHRM2, CHRNA2 | MTNR1A 280/4885MTNR1B 333/4885CA1 384/4885 |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | MTNR1A 604/4885MTNR1B 448/4885CA1 2237/4885 |
| US-20060058396-A1 | Amide compounds for the potentiation of cholinergic activity | CHRM2, CHRM1, CHAT | MTNR1A 253/4885MTNR1B 287/4885CA1 505/4885 |
| US-20030096847-A1 | Amide compounds for the potentiation of cholinergic activity | CHAT, CHRM2, CHRNA2 | MTNR1A 280/4885MTNR1B 333/4885CA1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.